Skip to main content
Caplight Logo









New Phase

New Phase

Private
IsraelHealthcare & Life Scienceshttps://newphase.co.il/

Last Round

Seed

Oct 22, 2025

Total Funding Raised

$35M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

New Phase is a biotechnology company that has developed a therapeutic technology based on nanoparticles designed to treat metastatic solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware + Subscription, Usage-Based SaaS, Government Contracts, Hardware Sales

AI Layer

Non-AI

Keywords

nanotechnology cancer treatmentmetastatic cancer treatmentsolid tumor treatmentmagnetic hyperthermiathermal ablationcancer nanomedicinenanoparticle therapymedtechmedical deviceoncology technologyminimally invasive therapyclinical stage

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

New Phase Comparables

Compare New Phase with similar companies based on industry and business-model similarity.

New Phase comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nanotherm Therapeutics, Inc.
84%
MagHeals
81%
Sona Nanotech
81%

New Phase Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 22, 2025
GrantJan 19, 2023

Key People

Founding team and executive leadership

Ofer Shalev

Founder & CEO Nanotechnology & Nanomaterials Expert

Founding Team

New Phase Investors

Notable investors and investment history

New Phase investors
InvestorRounds
BIRD FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    Monthly visitors grew 36% MoM.

  • Jan 5, 2026

    Monthly visitors increased 48% MoM.

Recent news

Latest coverage and updates

  • launchesJul 24, 2026

    New Phase Ltd. launched SARAH Nanoparticle Electromagnetic Hyperthermia Platform on Mar 1st '26.

  • hiresJul 22, 2026

    New Phase Ltd. hired Geschwind as scientific advisory board for oncology treatment on Jul 22nd '26.

New Phase Filings

Explore SEC and related filing metadata, where available.

New Phase filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about New Phase's valuation, stock price, and market status.

Is New Phase a public or private company?

New Phase is a private company.

What is the current stock price of New Phase?

New Phase is a private company with no public stock price. No recent secondary market data is available.

How much is New Phase worth (valuation)?

Valuation information for New Phase is not publicly available.

Can I buy New Phase stock?

New Phase shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was New Phase's last funding round?

New Phase's most recent funding round was Seed on October 22, 2025.

Who are the main investors in New Phase?

Key investors in New Phase include BIRD Foundation.

Will New Phase IPO soon?

No public IPO plans have been announced for New Phase.

How can I track New Phase secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor New Phase's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Employee Range18
Year Founded2013
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?